PROMISE Trial Substudy Demonstrates That the Corus CAD

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
PROMISE Trial Substudy Demonstrates That the Corus CAD Blood Test Is Associated With Clinical Events Among Patients Being Evaluated for Suspected Obstructive Coronary Artery Disease

REDWOOD CITY, CA--(Marketwired - Apr 4, 2016) - CardioDx, Inc. , a molecular diagnostics company specializing in cardiovascular genomics , announced today results from a genomic substudy of the NHLBI-funded Prospective Multicenter Imaging Study for Evaluation of Chest Pain (PROMISE) trial in nondiabetic patients receiving the Corus CAD blood test. The test integrates age, sex and gene expression into a single score (1-40 scale) corresponding to the likelihood of obstructive coronary artery disease (CAD).* Findings from the substudy were presented at the 65 th American College of Cardiology Annual Scientific Meeting, on April 3, 2016, in Chicago, IL.

In this study, the PROMISE Trial investigators asked if a blood-based, age- and sex-adjusted, gene expression score (ASGES or Corus CAD), previously validated for the detection of obstructive CAD, was also predictive of CAD events. The primary analysis showed that cardiovascular event rates, as defined by the composite rate of death, myocardial infarction (MI), hospitalization for unstable angina, or revascularization, were associated with the Corus CAD test in a score-dependent manner: Patients with higher Corus CAD test scores ( > 15, n=1312 patients) had higher event rates that were statistically different from patients with lower Corus CAD test scores (1-15, n=1058 patients) (odds ratio of 2.6, p < 0.001). Additionally, the results from the substudy found that at 25-month median follow-up, the clinical event rates for patients with low Corus CAD scores (≤ 15), were low and no different from negative or normal noninvasive test results using either cardiac stress testing or coronary CT-angiography (CTA) (3.2% vs. 2.6%, p=0.29). This relationship between Corus CAD test scores and event rates remained significant after adjusting for common clinical risk factors using the Framingham Risk Score (FRS) and provided independent and incremental information beyond noninvasive test results (stress testing or CTA). Lastly, the increased risk of clinical events seen with higher Corus CAD scores were largely driven by an increased rate of revascularization procedures in this group, thus reaffirming that the likelihood of obstructive CAD (defined as > 70% stenosis by CTA) increases with Corus CAD scores.

The study utilized 2,370 non-diabetic patients from the PROMISE trial biobank repository. Almost half of the patients in the substudy were randomized to the CTA arm (n=1,137). In this group, 10.1% of patients (n=115 of 1,137) were found to have obstructive CAD, and a Corus CAD score > 15 was associated with increased obstructive CAD likelihood (OR 2.5, p < 0.001). Findings from the PROMISE Trial provide independent confirmation of the association between the Corus CAD test scores and the presence and extent of coronary artery disease in patients and the likelihood of obstructive CAD.

"Findings from this PROMISE substudy demonstrate the opportunity to use a simple blood test in the initial evaluation of symptomatic patients with suspected CAD to help clinicians determine next steps and make clinical decisions," said Deepak Voora, M.D. Assistant Professor of Medicine, Duke Center for Applied Genomics & Precision Medicine. "The lower likelihood of not only CAD but risk of revascularization procedures seen in patients with low scores suggests that the score, in conjunction with a physician's clinical assessment, could provide additional information to help physicians efficiently and effectively rule out clinically significant obstructive CAD in the outpatient setting."

"We are very excited to see that the results from the large genomic substudy from the NIH-funded PROMISE Trial independently corroborate findings from our earlier Corus CAD clinical studies on the clinical validity of the test in the evaluation of obstructive CAD. In addition, while we have seen that in previous studies that patients with low Corus CAD test scores have a very low likelihood of major cardiac events within a one-year follow up period, it is very reassuring that the PROMISE substudy results confirm and extend this finding with greater than two years of follow-up seen here," said Mark Monane, M.D., FACP, Chief Medical Officer of CardioDx. "Lastly, we note the finding that clinical outcomes among the patients with the low scores on the Corus CAD blood test (approximately 45% of the study patients) were no different from patients with normal cardiac stress testing or CT-angiography. Taken together, these three results highlight the characteristics of the Corus CAD test to safely and accurately help clinicians risk stratify symptomatic patients, so that patients can potentially avoid additional cardiac testing and procedures that may be potentially unnecessary."

About Obstructive Coronary Artery Disease Coronary artery disease (CAD) is a very common heart condition in the United States. One in seven deaths among Americans is caused by CAD. 1 CAD can cause a narrowing or blockage of the coronary arteries (vessels to the heart that supply the heart with blood, oxygen, and nutrients), reducing blood flow to the heart muscle. This narrowing or blockage in the coronary arteries is often referred to as obstructive CAD, characterized by the presence of atherosclerosis, or plaque.

About the PROMISE Trial Sponsored by Duke University in collaboration with the National Heart Lung and Blood Institute (NHLBI) the Prospective Multicenter Imaging Study for Evaluation of Chest Pain (PROMISE) is the first large randomized trial using clinical outcomes to compare alternative diagnostic strategies for assessment of patients with new stable symptoms suggestive of coronary artery disease (CAD). 2

As part of the trial, a genomic archive of blood samples from study patients was obtained which included genetic material (DNA), genomic material (RNA) and plasma. CardioDx purified and isolated DNA and RNA using proprietary methods. In addition, the company's Corus CAD blood test was used to evaluate blood samples from an estimated 2,500 to 3,000 non-diabetic patients enrolled in the trial, with the goal of determining the test's ability to predict major clinical cardiovascular events.

About the Corus CAD Test Corus CAD is the first and only commercially available blood test that can safely and conveniently help primary care clinicians and cardiologists assess whether or not a stable non-diabetic patient's symptoms may be due to obstructive coronary artery disease. The test incorporates age, sex and gene expression measurements into a single score that indicates the likelihood of obstructive CAD. Clinicians use the Corus CAD score, along with other clinical information, to determine whether further cardiac testing is necessary, which can help patients avoid unnecessary exposure to radiation associated with medical imaging testing, as well as possible reactions to imaging dyes and/or potential complications from invasive cardiac tests requiring catheterization. The test involves a routine blood draw that is conveniently administered in the clinician's office or clinical laboratory patient service center. The Corus CAD test is the only sex-specific test for the evaluation of obstructive CAD because it accounts for cardiovascular differences between men and women.

The test has been clinically validated in independent male and female patient cohorts, including two prospective, multicenter U.S. studies, PREDICT and COMPASS. 3,4  In the COMPASS study, the Corus CAD test outperformed myocardial perfusion imaging (MPI) as a diagnostic tool to exclude obstructive CAD by demonstrating a higher negative predictive value (96% vs. 88%, p < 0.001) than MPI for assessing the presence of obstructive CAD. 5 To date, over 150,000 Corus CAD test results have been provided to clinicians. CardioDx processes all Corus CAD test samples at its CLIA-certified and CAP-accredited clinical laboratory in Redwood City, California.

The Corus CAD test has been recognized by The Wall Street Journal 's Technology Innovation Awards, honored as a Gold Edison Award recipient, and named one of TIME 's Top 10 Medical Breakthroughs.

About CardioDx CardioDx, Inc., a molecular diagnostics company specializing in cardiovascular genomics, is committed to developing clinically validated tests that empower clinicians to better tailor care to each individual patient. Strategically focused on coronary artery disease, CardioDx is committed to expanding patient access and improving healthcare quality and efficiency through the commercialization of genomic technologies. Please visit www.cardiodx.com for additional information.

* Obstructive CAD is defined as at least one atherosclerotic plaque causing ≥50% luminal diameter stenosis in a major coronary artery (≥1.5 mm lumen diameter) as determined by invasive quantitative coronary angiography (QCA) or coronary computed tomography angiography (CTA) (≥2.0 mm).

References

1 Mozaffarian D, Benjamin EJ, Go AS, et al. On Behalf of the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart Disease and Stroke Statistics - 2015 Update: A Report from the American Heart Association. Circulation . 2015;131(4):e29-e322. 2 Douglas PS, Hoffman U, Patel MR, et al. Outcomes of Anatomical Versus Functional Testing for Coronary Artery Disease. N Engl J Med. 2015;372(14):1291-1300. 3 Rosenberg S, Elashoff MR, Beineke P, et al. Multicenter Validation of the Diagnostic Accuracy of a Blood-Based Gene Expression Test for Assessing Obstructive Coronary Artery Disease in Nondiabetic Patients. Ann Intern Med . 2010;153:425-434.  4 Thomas GS, Voros S, McPherson JA, et al. A Blood-Based Gene Expression Test for Obstructive Coronary Artery Disease Tested in Symptomatic Nondiabetic Patients Referred for Myocardial Perfusion Imaging: The COMPASS Study. Circ Cardiovasc Genet . 2013;6(2):154-162. 5 The COMPASS study demonstrated that the Corus CAD algorithm has an NPV of 96% at the pre-specified threshold of 15 in a population of men and women referred to MPI.

For media inquiries, please contact Glenn Silver Lazar Partners +1-212-871-8485 gsilver@lazarpartners.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Hanmi Compressor Tests Vietnam Before Wider Expansion

Updated Category News Views 29

Compressed air is the sort of factory necessity nobody brags about until it fails, and that is precisely why Hanmi Compressor’s Vietnam plan deserves a sober look. The Daegu-based specialist is not arriving with a grand export victory lap. It is still building the front door: a website, a promotional video, and a process for finding Vietnamese manufacturers and...

Continue Reading
Alpha's Training Bet Reaches Into Aesthetic Care Networks

Updated Category News Views 213

Training is becoming part of the operating machine A certificate course is rarely the headline-grabber in healthcare services, yet this one deserves a closer look. Alpha Aesthetics Partners has launched Practice Aesthetics, a unified clinical education platform tied directly to its expanding network of medical aesthetics practices. This is not a public-market ticker...

Continue Reading
STORMER LAT Targets Sewer Crews' Costly Access Delays

Updated Category News Views 65

A buried cleanout can turn a simple sewer inspection into a scheduling circus. That unglamorous headache is exactly where FIBERSCOPE is aiming its new STORMER LAT Lateral Launch Camera System, announced November 17, 2026. This is not some flashy consumer gadget hunting for attention; it is field equipment built around a painfully ordinary municipal problem: crews often...

Continue Reading
MacDill Mold Case Puts Privatized Housing on Notice

Updated Category News Views 99

Four hundred fifty-four people are a hard number to shrug off. The expanded civil case over alleged toxic mold conditions at MacDill Air Force Base now covers 105 military families, up from 39 households when it was filed in September 2025. Their complaint against The Michaels Organization and affiliated entities may be the largest known military-housing lawsuit in the...

Continue Reading
Historic China-Russia-US Summit Aims for Global Stability

Updated Category News Views 85

The Weight of History in Shenzhen When the big players decide to talk face-to-face, it's more than just a photo op. This week in Shenzhen, the leaders of China, Russia, and the United States are doing just that. And let me tell you, it's the kind of gathering that can either stabilize the gears of global politics or grease the wheels of tension. This chinwag isn't just...

Continue Reading
Inhibrx Ewing Data Gives Ozekibart a Real Clinical Signal

Updated Category News Views 141

Numbers this lopsided in relapsed Ewing sarcoma make me sit up straight, even after years of watching oncology releases try to turn every blip into a brass band. Inhibrx has reported updated Phase 1/2 data for ozekibart, paired with irinotecan and temozolomide, that look genuinely notable in a disease where patients have very few good cards left to play. That matters...

Continue Reading
BioArctic's Q3 Call Puts Leqembi Economics Under Watch

Updated Category News Views 32

One Date, Several Unanswered Questions November 25 lands with an unusually clean checklist for BioArctic watchers: results arrive at 8:00 a.m. CET, then management takes the floor at 9:30 a.m. CET. That is the whole immediate event, and it matters because this is not a company investors can sensibly judge by a single headline or a vague promise about neuroscience....

Continue Reading
LONGi's Solar-Storage Push Faces Africa's Cost Wall

Updated Category News Views 22

A vaccine refrigerator humming through a blackout is more meaningful than another climate-conference slogan. That was the useful thread running through LONGi's November 13 COP31 side event in Antalya, Türkiye: solar and storage are not merely hardware for remote communities. When designed, financed and maintained properly, they can keep clinics, water pumps and other...

Continue Reading
Visa Direct Tests Stablecoin Prefunding in Asia-Pacific

Updated Category News Views 149

Cross-border payouts have always had an ugly little problem: money can move digitally in theory, then sit around waiting for banks to wake up in practice. Triple-A’s new collaboration with Visa Direct aims straight at that nuisance in Asia-Pacific, allowing eligible clients to use stablecoins to prefund cross-border payouts while the recipient still gets local currency....

Continue Reading
Midea's Cooling Systems Take Center Stage at DCW ME

Updated Category News Views 121

AI Surge Demands Cooler Solutions Alright, who'd guess that data centers would feel the heat—literally—like a welder's furnace in Abu Dhabi? As AI demand burns hotter across the Middle East, data centers are sweating it out against 50°C-plus temperatures. We're talking about some serious pressure on traditional cooling methods that just can’t cut it anymore....

Continue Reading

Top 5 Most Recently Viewed Articles

Streamlined Shipping Solutions for UK Businesses by Wix.com

Updated Category News Views 279

Enhancing Shipping for UK Businesses with Wix.com Wix.com Ltd. (NASDAQ: WIX) has taken a significant step forward in supporting UK businesses by integrating Royal Mail within its innovative Wix Shipping platform. This breakthrough means that merchants can now easily transition from traditional, manual shipping processes to a fully automated system, streamlining their...

Continue Reading
FullFlex.Agency Innovation: AI Solutions for Business Growth

Updated Category News Views 147

FullFlex.Agency Unleashes Innovative Marketing Solutions FullFlex.Agency is celebrating its continued success as it enters the fourth quarter of its second year. This dynamic organization, known for its robust AI-powered marketing solutions and transparent pricing structures, emphasizes its commitment to helping businesses thrive across various sectors. Expansion of...

Continue Reading
NexBank Achieves Recognition as Leading Mortgage Lender

Updated Category News Views 207

NexBank: A Consistent Leader in Mortgage Lending NexBank has once again made headlines by being recognized as one of the top mortgage lenders in the nation for the fourth consecutive year. This achievement underscores the bank's ongoing commitment to excellence in the mortgage industry. The latest rankings show that NexBank secured the 12th position for Correspondent...

Continue Reading
First Mining Gold Corp. Strengthens Position with First Majestic

Updated Category News Views 173

Key Agreement Enhancements Between First Mining Gold and First Majestic First Mining Gold Corp. (TSX: FF) has announced an important agreement with First Majestic Silver Corp. that is expected to positively impact its financial position and operational strategy. This mutually beneficial arrangement revises the parameters of the existing silver purchase agreement,...

Continue Reading
Expert Weighs In: College Apps Need Strategy, Not Count

Updated Category News Views 38

A Lesson for College-Bound Families When the question comes up about college applications, you expect to hear numbers thrown around like eight, twelve, or even twenty. But the idea that there's some magic number to crack the admissions code? It just doesn't hold water. Instead, it's all about the risk baked into your list of schools. That's where HelloCollege's recent...

Continue Reading